842133-18-0
![(1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇](https://stcdn.activebiopharma.com/active/ABP000358.png)
842133-18-0
编号ABP000358
化学名称(1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇
英文名称 Canagliflozin/
MDL: MFCD18251436
分子式C24H25FO5S
分子量444.521
纯度 >98%
化学名称 : (1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇
CAS : 842133-18-0
英文名称: Canagliflozin/
英文同义词: CANAGLIFLOZIN
溶解度:Unknown
储存条件:at -20℃ 2 years
生物活性
Canagliflozin is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.[1][2] It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3]
参考文献
- ^ New J&J diabetes drug effective in mid-stage study, Jun 26, 2010
- ^ Edward C. Chao (2011). "Canagliflozin". Drugs of the Future 36 (5): 351-357. doi:10.1358/dof.2011.36.5.1590789.
- ^ Prous Science: Molecule of the Month November 2007
-
Abiraterone(CB-7598)/CB7598
154229-19-3
-
![N-[2-氯-4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(5-甲基-3-异恶唑基)脲](https://stcdn.activebiopharma.com/active/ABP001003.png)
N-[2-氯-4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(5-甲基-3-异恶唑基)脲
475108-18-0
-
紫杉醇
33069-62-4
-
17-DMAG/17 DMAG,Geldanamycin
150270-08-9
Copyright © 2015-2025 活性医药. All rights reserved. Support by Moldb.
浙公网安备 33010802003999号